Notice: 

Due to customs policies in different countries, this product cannot be 100% successfully shipped to any country. Please contact our customer service before placing an order and we will arrange shipping after confirmation.

Hot Selling Peptide Products 2024:

>>Make inquiry online:  Click here

>>Inquiry by mail: [email protected]

Buy Tirzepatide Peptide 10mg Online | Omizzur Peptide

Tirzepatide peptide, developed by Lilly in the United States, is a new hypoglycemic drug approved by the FDA in 2022.

Tirzepatide has a similar sequence to semaglutide. Tirzepatide with the lys side chains in the sequence modified with PEG, which are functional groups of peptides and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is a double agonist of GIP and GLP-1 receptor. It can be used to treat type 2 diabetes.

In the SURMOUNT-1 study, researchers selected 2539 patients with a BMI of 30 or 27 or greater and obesity complications. Through experiments, Tirzepatide achieved a weight loss of about 20%. About one-third of patients achieved weight loss of over 25%. It almost achieving surgical results.

The research results found that the average weight of participants at baseline was 104.8kg, with an average BMI of 38.0, and 94.5% of participants had a BMI of 30 or greater. At week 72, the weight change was -15.0% (-15.9 to -14.2), -19.5% (-20.4 to -18.5) for 5 milligrams, -20.9% (-21.8 to -19.9) for 10 milligrams, and -3.1% (-4.3 to -1.9) for 15 milligrams. The proportion of weight loss above 5% was 85% (82 to 89), 89% (86 to 92), and 91% (88 to 94), respectively, compared to 35% (30 to 39) in the placebo group. 50% (46 to 54) and 57% (53 to 61) of patients in the 10 mg and 15 mg groups lost more than 20% of their weight.

Patients using Tirzepatide can observe improvements in all metabolic indicators. The most common adverse event of texaparide is mild to moderate gastrointestinal reactions, mainly occurring during dose escalation.

Tirzepatide has a half-life of 116.7 hours and is metabolized in the body for 5 days. There are a total of 6 doses of this injection, which patients can inject on their own. It is better to improve the blood sugar level of type 2 diabetes patients on the basis of combined diet and exercise by giving drugs once a week. The study found that in addition to controlling the blood sugar level of patients with type 2 diabetes, there is also great potential in fatty liver and cardiovascular disease and so on.

Tirzepatide Structure 

Tirzepatide, a weekly GIP and GLP-1 receptor agonist used for injection. It is a 39 amino acid of peptide based on the GIP sequence. At positions 2 and 13, It contains two non coding amino acids (Aib), a C-terminal amide, and a Lys residue at position 20. It is connected to 1,20-eicosanedioic acid through a connector. The molecular weight is 4813.53 Da, and the formula is C225H348N48O68. The structure is as follows:

Tirzepatide vs Semaglutide

According to the latest SURMONT-3 and SURMONT-4 trial results released by Lilly, participants receiving Tirzepatide treatment experienced a total average weight loss of 26.6% after 12 weeks of intensified lifestyle intervention and continued use of Tirzepatide for 72 weeks

According to clinical data released by Novo Nordisk in May this year, after 68 weeks of treatment, oral administration of 50mg of Rybelsus can reduce weight by up to 17.4% (adherence to medication). If patients stop taking medication for some reason or forget to take it, the weight loss effect can reach 15.1%. Tirzepatide is undoubtedly the strongest weight loss drug in history.

Tirzepatide Fewer Side Effects

Of course, Tirzepatide also has side effects, but compared to smeglutide, the side effects of telposide may be milder.

The research results show that 80% of users of Tirzepatide reported at least one side effect, with the majority showing nausea, diarrhea, constipation, or vomiting - which is also a common side effect of semaglutide.

In clinical trials, 33% of patients taking the highest dose of Tirzepatide reported nausea, while 44% of patients taking smeglutide reported this proportion. 23% of patients with Tirzepatide reported diarrhea, while the proportion of patients with smeglutide was 31%.

Although Tirzepatide may also cause some adverse reactions such as nausea, vomiting, diarrhea, etc., these symptoms are usually mild and can be tolerated by patients. Compared with traditional diabetes drugs, Tirzepatide has lower incidence of side effects and higher safety.

Tirzepatide supply in bulk from Omizzur biotech.

Management 

(1) Once a week, can be taken at any time of the day, with or without meals.

(2) Inject subcutaneously into the abdomen, thighs, or upper arms, and rotate the injection site after each dose.

(3) Visual text before use shows that this product should be transparent, colorless to slightly yellow. If discoloration of particulate matter is found, do not use it. When used with insulin, please do not mix. Injecting this product and insulin into the same body part is acceptable, but two injections should not be same position.

1. Store Tirzepatide in a fridge at 2 ℃ to 8 ℃.

If necessary, each single dose can be stored without fridge for up to 21 days at a temperature not over 30 ℃.

3. Do not freeze Tirzepatide. If frozen, do not use Tirzepatide.

4. Store the Tirzepatide in the box, avoiding light exposure.

5. Shipping by Fedex / DHL / EMS, deliver in 5-10 days.

Customer Service Center

 Quote Request :

 [email protected]

  * Please mail us your product name and quantity needed, Omizzur customer services will get in touch with you within 1 hour.

References

1. DAHL D, ONISHI Y, NORWOOD P, et al. Effect of Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Clinical Trial.[Z]. 2022: 327, 534-545.

2. COSKUN T, SLOOP K W, LOGHIN C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes : From discovery to clinical proof of concept.[Z]. 2018: 18, 3-14

3. HARTMAN M L, SANYAL A J, LOOMBA R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Patients With Type 2 Diabetes.[Z].buy Tirzepatide peptide 10mg for sale online  2020: 43, 1352-1355